Main points of design about phase I tolerant clinical trials of injectable preparation

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2007, Vol. 12 ›› Issue (3): 346-348.

Previous Articles Next Articles

Main points of design about phase I tolerant clinical trials of injectable preparation

HAN Rong, XUE Jie, QI Jian-guo

Affiliated Hospital of Traditional Chinese Medicine, Xinjiang Medical University, Urumqi 830000, Xinjiang, China

Received:2007-02-13 Revised:2007-03-18 Online:2007-03-26 Published:2020-11-06

Abstract

Abstract: In order to consummate the various specification in phase I tolerant clinical trials, through using medicine dosage, increasing the dosage plan, the treatment course, choosing the fluid, giving the medicine method, stochastically entering the group, the physics and chemistry result judgment, human body responding aspect and so on, we summarize and propose the standard sequence of operation.It proves effective to improve the quality from the clinical trials.

Key words: phase I, tolerant trials, clinical trials

CLC Number:

R969

HAN Rong, XUE Jie, QI Jian-guo. Main points of design about phase I tolerant clinical trials of injectable preparation[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(3): 346-348.

[1]	WANG Zhi, ZHOU Xin, HE Xueru, FU Yuhao, XUN Xuejiao, LI Ying, DONG Zhanjun. Clinical research progress of palbociclib in treatment of breast cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 205-213.
[2]	DAI Jiahui, SUN Sijia, XIE Xuefeng. Quality management and indicator system for clinical trials of medical devices [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 51-58.
[3]	CHEN Jianfang, LOU Donghua. Design of case report form for oncology clinical trials based on CDASH [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 762-767.
[4]	LIU Xing, LU Xiaoran, WU Ying, YU Haitao, WANG Xiaomin. Ethical analysis and countermeasures of artificial intelligence application in clinical trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 322-327.
[5]	ZHU Lili, ZHU Xiuxiu, WANG Wenjun, ZHANG Hailin, LIN Li. Clinical trials of inhalation in pediatric population in China [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 178-183.
[6]	ZHENG Ying, ZHANG Ling, YAO Li, WANG Qianhe, ZHU Kexiang. Research progress of PARP inhibitors in pancreatic cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(1): 108-115.
[7]	SHE Zhihua, CHEN Zhou, LIANG Songyue. Construction of informatization system of drug clinical trials ethical review based on cloud architecture [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1023-1030.
[8]	SONG Yan, GAO Linyan, ZHANG Yanping, LI Xiang, ZHANG Lan. Application of medical failure mode and effect analysis in blood sample management in phase I clinical trials#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(9): 1031-1036.
[9]	OUYANG Chenxi, HUANG Jie, XIANG Yuxia, WANG Xiaomin. Ethical issues and countermeasures of early phase trials [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(7): 802-807.
[10]	Pazilaiti YASEN, YUAN Hao, LU Hong, ZHENG Ya, WANG Yuping, ZHOU Yongning. Research progress in clinical trials of targeted drugs for gastric cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 454-461.
[11]	ZHANG Qian, HU Wei, YU Bin, QIN Huiling, CHEN Mingzhuang, LU Chao. Information construction of drug clinical trials based on literature analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 182-189.
[12]	YU Zhaolei, BAI Jianling, YU Hao, ZHAO Yang. Development of tools for clinical trial information retrieval and Meta-analysis based on R-Shiny: Taking non-small cell lung cancer as an example [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 984-991.
[13]	JIANG Haihong, LI Xiao, LIU Yang. Four dimensions of receiving overseas clinical trial data about drug and medical devices [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(7): 835-840.
[14]	ZHONG Zihang, CHEN Feng, YUAN Ying, CHENG Jiancheng, YU Xuanxuan, YANG Min, TAN Mingmin, ZHAO Yang, BAI Jianling, YU Hao. A novel model-assisted design in phase I clinical trials: Bayesian optimal interval design [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 640-648.
[15]	ZHANG Yu, PENG Ying, WANG Guangji, SUN Jianguo. Advances in study of phase II metabolic enzyme expression and activity under diseases status [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 686-700.

Main points of design about phase I tolerant clinical trials of injectable preparation

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments